Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarial and cancer medicines. Roche has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland is active in over 150 countries and in 2019 employed about 97,000 people worldwide. The company is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. In 2019, Roche invested USD 12 billion in R&D. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche in Kazakhstan*
In 1993, Roche became one of the first global pharmaceutical companies, which opened a representative office in Almaty, Kazakhstan. As a socially responsible company, Roche actively supports the introduction of modern methods of diagnosis and treatment of socially significant diseases, and makes an active contribution to the development of the country's healthcare system. Today, Kazakhstan is one of the priority regions of work in terms of conducting clinical trials developing diagnostics and providing local patients with access to innovative therapies to treat cancer, neurological and hematological diseases, as well as carrying out research and educational events.